Tumor Infiltrating Lymphocytes Global Market Report 2024

The tumor infiltrating lymphocytes market size has grown rapidly in recent years. It will grow from $9.34 billion in 2023 to $10.72 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth observed in the historical period can be attributed to several factors, including the rise in cancer incidence rates, increased funding for research initiatives, regulatory approvals for cancer treatments, heightened awareness about cancer-related issues, and notable clinical successes showcasing the efficacy of various treatments.

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $18.32 billion in 2028 at a compound annual growth rate (CAGR) of 14.3%. The projected growth in the forecast period is driven by several factors, including advancements in pipeline developments, a rise in healthcare expenditure, the emergence of new markets, strategic collaborations and alliances, continued regulatory support, and growing demand from patients for innovative treatments. Key trends expected in the forecast period encompass significant advancements in immunotherapy, increased focus on research and development initiatives, evolving regulatory landscapes impacting the healthcare sector, the expanding scope of personalized medicine, and heightened market competition within the industry.

The increasing prevalence of cancer patients is anticipated to drive the growth of the tumor-infiltrated lymphocytes (TIL) market. Cancer, characterized by uncontrolled cell growth and spread in the body, poses significant health challenges, some of which can be life-threatening. Tumor-infiltrating lymphocytes, a specific type of immune cell, play a crucial role in identifying and eliminating cancer cells. These lymphocytes are harvested from a patient's tumor, extensively cultured in a laboratory, and subsequently reintroduced into the patient to support the immune system in targeting and destroying cancer cells. Notably, as of January 2022, the American Cancer Society reported projections of 1,918,030 new cancer cases and 609,360 cancer-related deaths for the year, highlighting an increase compared to 2020 figures of 1,806,590 new cancer cases and 606,520 projected deaths. This rise in cancer cases underscores the driving force behind the expansion of the tumor-infiltrated lymphocyte market.

The growing demand from patients for personalized therapies is poised to fuel the growth of the tumor-infiltrating lymphocyte market in the foreseeable future. Personalized therapies involve tailoring medical treatments to an individual's distinct characteristics, including genetic makeup, molecular traits, lifestyle, and environmental influences. The incorporation of tumor-infiltrating lymphocytes in customized treatments aims to enhance cancer treatment strategies by leveraging the unique immune profiles of each patient. In February 2023, the Personalized Medicine Coalition reported that personalized medications constituted 34% of new drug approvals by the US Food and Drug Administration in 2022, contributing to at least 25% of approvals in each of the preceding eight years. The increasing patient demand for personalized therapies emerges as a key driver propelling the growth of the tumor-infiltrating lymphocyte market.

Technological advancements emerge as a prominent trend gaining traction in the tumor-infiltrating lymphocytes market, with major companies strategically focusing on developing cutting-edge solutions to enhance their market positions. An illustrative example is Obsidian Therapeutics Inc., a US-based biotechnology firm specializing in engineered tumor-infiltrating lymphocytes (TIL cells) and gene treatments. In May 2022, Obsidian Therapeutics announced the introduction of cytoDRIVE technology, showcasing its ability to precisely regulate the time and level of protein activity using FDA-approved small chemicals. This technological innovation holds significant potential for treating solid cancers by employing potent cytokines such as IL12 to support cell treatments. The study revealed that various cytokines, including IL12, IL23, IL2, and IFN, could be robustly and reversibly regulated, potentially enabling their safe utilization in adoptive cell therapy applications.

Major players in the tumor-infiltrating lymphocytes market are adopting a strategic partnership approach to foster the development of innovative treatments centered around gene editing. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits. In April 2021, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, entered into a partnership licensing agreement with Obsidian Therapeutics Inc. The collaboration is dedicated to advancing groundbreaking medicines that control gene editing for the treatment of critical disorders. Vertex's well-established scientific and clinical capabilities in small molecule, cell, and genetic therapies are complemented by Obsidian's cytoDRiVE platform technology. This technology allows the development of gene-editing drugs with easily controlled therapeutic activity using small molecules. The collaboration aims to expedite the delivery of these innovative approaches to patients. By building on and expanding Vertex's expertise in small molecules and genetic medicines, the partnership with Obsidian positions Vertex at the forefront of advancements in controlled cell and gene treatments.

In January 2021, Turnstone Biologics Corporation, a leading US-based diagnostic biotechnology firm specializing in cancer immunotherapies, successfully acquired Myst Therapeutics Inc. The acquisition, conducted for an undisclosed amount, grants Turnstone Biologics Corp. exclusive access to Myst Therapeutics Inc.'s cutting-edge technology, comprehensive research and development resources, existing development partnerships, and a robust portfolio of tumor-infiltrating lymphocytes (TIL) projects. Myst Therapeutics Inc., a prominent US-based biotechnology company, is dedicated to advancing cancer immunotherapies through the utilization of tumor-infiltrating lymphocytes (TIL) and the development of innovative T-cell therapeutics designed for the treatment of solid tumors.

Major companies operating in the tumor infiltrating lymphocytes market report are Bellicum Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Precision BioScience Inc., Bluebird Bio Inc., TCR2 Therapeutics Inc., Fate Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Seeking Alpha Ltd., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Editas Medicine Inc., Intellia Therapeutics Inc., Kiadis Pharma N.V., MaxCyte Inc..

North America was the largest region in the tumor infiltrating lymphocytes market in 2023. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key components or anatomies of tumor-infiltrating lymphocytes encompass CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. CD3, also known as the cluster of differentiation 3, constitutes a complex protein structure involving T-cells, B-cells, and natural killer cells. These components find applications in various cancers such as melanoma, cervical cancer, ovarian cancer, among others. The end-users of these lymphocytes include hospitals, cancer research centers, and clinics involved in cancer treatment and research.

The tumor infiltrating lymphocytes market research report is one of a series of new reports that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.